Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (61)
  • Open Access

    REVIEW

    Therapeutic and regenerative potential of different sources of mesenchymal stem cells for cardiovascular diseases

    YARA ALZGHOUL, HALA J. BANI ISSA, AHMAD K. SANAJLEH, TAQWA ALABDUH, FATIMAH RABABAH, MAHA AL-SHDAIFAT, EJLAL ABU-EL-RUB*, FATIMAH ALMAHASNEH, RAMADA R. KHASAWNEH, AYMAN ALZU’BI, HUTHAIFA MAGABLEH

    BIOCELL, Vol.48, No.4, pp. 559-569, 2024, DOI:10.32604/biocell.2024.048056

    Abstract Mesenchymal stem cells (MSCs) are ideal candidates for treating many cardiovascular diseases. MSCs can modify the internal cardiac microenvironment to facilitate their immunomodulatory and differentiation abilities, which are essential to restore heart function. MSCs can be easily isolated from different sources, including bone marrow, adipose tissues, umbilical cord, and dental pulp. MSCs from various sources differ in their regenerative and therapeutic abilities for cardiovascular disorders. In this review, we will summarize the therapeutic potential of each MSC source for heart diseases and highlight the possible molecular mechanisms of each source to restore cardiac function. More >

  • Open Access

    ARTICLE

    Overexpression of RUNX1 mitigates dexamethasone-induced impairment of osteogenic differentiation and oxidative stress injury in bone marrow mesenchymal stem cells by promoting alpha-2 macroglobulin transcription

    QINGJIAN HE1, HUIXIN ZHU2,3, SHANHONG FANG4,5,*

    BIOCELL, Vol.48, No.2, pp. 205-216, 2024, DOI:10.32604/biocell.2023.045109

    Abstract Introduction: Dexamethasone (Dex) caused impaired osteoblast differentiation and oxidative stress (OS) in bone marrow mesenchymal stem cells (BMSCs). This work sought to elucidate the precise molecular pathway through which Dex influences osteogenic differentiation (OD) and OS in BMSCs. Methods: The expression of Runt-related transcription factor 1 (RUNX1) and alpha-2 macroglobulin (A2M) was assessed in Dex-treated BMSCs using qRT-PCR and Western Blot. Following the functional rescue experiments, cell proliferation was determined by MTT assay, reactive oxygen species (ROS) expression by DCFH-DA fluorescent probe, lactate dehydrogenase (LDH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (Gpx) expression by kits, OD by alkaline… More >

  • Open Access

    REVIEW

    Mesenchymal stem cells and the angiogenic regulatory network with potential incorporation and modification for therapeutic development

    VAN THI TUONG NGUYEN1,2, KHUONG DUY PHAM1,2,3, HUONG THI QUE CAO1,2, PHUC VAN PHAM1,2,*

    BIOCELL, Vol.48, No.2, pp. 173-189, 2024, DOI:10.32604/biocell.2023.043664

    Abstract Mesenchymal stem cells (MSCs) have been proposed in regenerative medicine, especially for angiogenic purposes, due to their potential to self-renew, differentiate, and regulate the microenvironment. Peripheral vascular diseases, which are associated with reduced blood supply, have been treated but not cured. An effective therapy is to recover blood supply via vessel regeneration in the affected area, and MSCs appear to be promising for such conditions. Several studies aimed to explore the role of MSCs in performing angiogenesis and have revealed numerous potential methods to enhance MSC capacity in vessel formation. Efforts have been made to modify standard MSCs to optimize… More > Graphic Abstract

    Mesenchymal stem cells and the angiogenic regulatory network with potential incorporation and modification for therapeutic development

  • Open Access

    ARTICLE

    Placenta-derived mesenchymal stem cells attenuate secondary brain injury after controlled cortical impact in rats by inhibiting matrix metalloproteinases

    PING YANG1,2,3, YUANXIANG LAN1,2, ZHONG ZENG1,2, YAN WANG1,2, HECHUN XIA1,2,*

    BIOCELL, Vol.48, No.1, pp. 149-162, 2024, DOI:10.32604/biocell.2023.042367

    Abstract Background: As a form of biological therapy, placenta-derived mesenchymal stem cells (PDMSCs) exhibit considerable promise in addressing the complex pathological processes of traumaticbrain injury (TBI) due to their multi-target and multi-pathway mode of action. Material & Methods: This study investigates the protective mechanisms and benefits of PDMSCs in mitigating the effects of controlled cortical impact (CCI) in rats and glutamate-induced oxidative stress injury in HT22 cells in vitro. Our primary objective is to provide evidence supporting the clinical application of PDMSCs. Results: In the in vivo arm of our investigation, we observed a swift elevation of matrix metalloproteinase-9 (MMP-9) in… More > Graphic Abstract

    Placenta-derived mesenchymal stem cells attenuate secondary brain injury after controlled cortical impact in rats by inhibiting matrix metalloproteinases

  • Open Access

    ARTICLE

    Inhibition of VEGF-A expression in hypoxia-exposed fetal retinal microvascular endothelial cells by exosomes derived from human umbilical cord mesenchymal stem cells

    JING LI1,2, WANWAN FAN4, LILI HAO1, YONGSHENG LI5, GUOCHENG YU1, WEI SUN6, XIANQIONG LUO2,*, JINGXIANG ZHONG1,3,*

    BIOCELL, Vol.47, No.11, pp. 2485-2494, 2023, DOI:10.32604/biocell.2023.044177

    Abstract Objective: This study aimed to investigate the potential of human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes (hucMSC-Exos) in inhibiting hypoxia-induced cell hyper proliferation and overexpression of vascular endothelial growth factor A (VEGF-A) in immature human fetal retinal microvascular endothelial cells (hfRMECs). Methods: Exosomes were isolated from hucMSCs using cryogenic ultracentrifugation and characterized through various techniques, including transmission electron microscopy, nanoparticle tracking analysis, bicinchoninic acid assays, and western blotting. The hfRMECs were identified using von Willebrand factor (vWF) co-staining and divided into four groups: a control group cultured under normoxic condition, a hypoxic model group, a hypoxic group treated with… More > Graphic Abstract

    Inhibition of VEGF-A expression in hypoxia-exposed fetal retinal microvascular endothelial cells by exosomes derived from human umbilical cord mesenchymal stem cells

  • Open Access

    REVIEW

    The role of mesenchymal stem cell-derived exosomes in tumor progression

    CARL RANDALL HARREL1, VALENTIN DJONOV2, ANA VOLAREVIC3, DRAGICA PAVLOVIC4, VLADISLAV VOLAREVIC4,5,*

    BIOCELL, Vol.47, No.8, pp. 1757-1769, 2023, DOI:10.32604/biocell.2023.028567

    Abstract Exosomes derived from mesenchymal stem cells (MSC-Exos) are nano-sized extracellular vesicles enriched with bioactive molecules, such as microRNAs, enzymes, cytokines, chemokines, immunomodulatory, trophic, and growth factors. These molecules regulate the survival, phenotype, and function of malignant and tumor-infiltrated immune cells. Due to their nano-size and bilayer lipid envelope, MSC-Exos can easily bypass biological barriers and may serve as drug carriers to deliver chemotherapeutics directly into the tumor cells. Here, we summarize current knowledge regarding molecular mechanisms responsible for MSC-Exos-dependent modulation of tumor progression and discuss insights regarding the therapeutic potential of MSC-Exos in the treatment of malignant diseases. More > Graphic Abstract

    The role of mesenchymal stem cell-derived exosomes in tumor progression

  • Open Access

    ARTICLE

    A novel mutation in ROR2 led to the loss of function of ROR2 and inhibited the osteogenic differentiation capability of bone marrow mesenchymal stem cells (BMSCs)

    WENQI CHEN1,#, XIAOYANG CHU2,#, YANG ZENG3,#, YOUSHENG YAN4, YIPENG WANG4, DONGLAN SUN1, DONGLIANG ZHANG5, JING ZHANG1,*, KAI YANG4,*

    BIOCELL, Vol.47, No.7, pp. 1561-1569, 2023, DOI:10.32604/biocell.2023.028851

    Abstract Background: Receptor tyrosine kinase-like orphan receptor 2 (ROR2) has a vital role in osteogenesis. However, the mechanism underlying the regulation of ROR2 in osteogenic differentiation is still poorly comprehended. A previous study by our research group showed that a novel compound heterozygous ROR2 variation accounted for the autosomal recessive Robinow syndrome (ARRS). This study attempted to explore the impact of the ROR2: c.904C>T variant specifically on the osteogenic differentiation of BMSCs. Methods: Coimmunoprecipitation (CoIP)-western blotting was carried out to identify the interaction between ROR2 and Wnt5a. Double-immunofluorescence staining was used for determining the expressions and co-localization of ROR2 and Wnt5a… More > Graphic Abstract

    A novel mutation in <i>ROR2</i> led to the loss of function of <i>ROR2</i> and inhibited the osteogenic differentiation capability of bone marrow mesenchymal stem cells (BMSCs)

  • Open Access

    ARTICLE

    Immunoregulatory effects of human amniotic mesenchymal stem cells and their exosomes on human peripheral blood mononuclear cells

    XIN TIAN, XIANGLING HE*, SHUQIN QIAN, RUNYING ZOU, KEKE CHEN, CHENGGUANG ZHU, ZEXI YIN

    BIOCELL, Vol.47, No.5, pp. 1085-1093, 2023, DOI:10.32604/biocell.2023.027090

    Abstract Background: The immunomodulatory effects of mesenchymal stem cells (MSCs) and their exosomes have been receiving increasing attention. This study investigated the immunoregulatory effects of human amniotic mesenchymal stem cells (hAMSCs) and their exosomes on phytohemagglutinin (PHA)-induced peripheral blood mononuclear cells (PBMCs). Methods: The hAMSCs used in the experiment were identified by light microscopy and flow cytometry, and the differentiation ability of the cells was determined by Oil Red O and Alizarin Red staining. The expressions of transforming growth factor (TGF)-β, indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2 (COX-2), hepatocyte growth factor (HGF), and interleukin (IL)-6 were detected by quantitative real-time polymerase chain reaction… More >

  • Open Access

    REVIEW

    Therapeutic application of mesenchymal stem cells-derived extracellular vesicles in colorectal cancer

    MOHADESEH NEMATI1, YOUSEF RASMI1, JAFAR REZAIE2,*

    BIOCELL, Vol.47, No.3, pp. 455-464, 2023, DOI:10.32604/biocell.2023.025603

    Abstract Colorectal cancer (CRC) is the third most common cancer and the leading cause of cancer death globally. Resistance to therapy is a challenge for CRC treatment. Mesenchymal stem cells (MSCs) have become one of the furthermost effective approaches for tumor treatment due to their specific feature; however, their therapeutic function is controversial. Recently, extracellular vesicles (EVs) derived from MSCs (MSCs-EVs) have attracted extensive research attention due to their promising role in CRC treatment. EVs are cell-derived vesicles that transfer different biomolecules between cells, contributing to intracellular communication. MSCs-EVs can suppress CRC by delivering therapeutic agents to tumor cells. Several studies… More >

  • Open Access

    ARTICLE

    The antioxidant trolox inhibits aging and enhances prostaglandin E-2 secretion in mesenchymal stem cells

    XIAOXU ZHANG1,2, LIN ZHANG1, LIN DU3, HUIYAN SUN4, XIA ZHAO2, YANG SUN1, WEI WANG2,*, LISHENG WANG1,3,*

    BIOCELL, Vol.47, No.2, pp. 385-392, 2023, DOI:10.32604/biocell.2023.025203

    Abstract Mesenchymal stem cells (MSCs) have been widely used in regenerative medicine and clinical therapy due to their capabilities of proliferation, differentiation, and immune regulation. However, during in vitro expansion, MSCs are prone to aging, which largely limits their application. Prostaglandin E-2 (PGE-2) is a key effector secreted by MSCs to exert immunomodulatory effects. By screening the compound library for PGE-2 secretion, the antioxidant trolox was verified as a stimulator of MSCs to secrete PGE-2. The effect of antioxidant trolox on biological characteristics of MSCS, including aging, proliferation, and gene expression, was examined. The results demonstrated that trolox can resist aging,… More >

Displaying 1-10 on page 1 of 61. Per Page